| |
Pneumonia
|
Non-pneumonia
|
p value
|
NHAI
|
Non NHAI
|
p value
|
|---|
|
n = 41
|
n = 19
|
n = 24
|
n = 36
|
|---|
|
Agea
|
73 (61–79)
|
76 (59–81)
|
0.744
|
78 (72–85)
|
71 (57–77)
|
0.004
|
|
Maleb
|
30 (73.2%)
|
12 (63.2%)
|
0.431
|
15 (62.5%)
|
27 (75.0%)
|
0.391
|
|
ARDS
|
8 (19.5%)
|
0 (0%)
|
0.047
|
4 (16.7%)
|
4 (11.1%)
|
0.702
|
|
Pneumonia
| | | |
23 (95.8%)
|
19 (52.8%)
|
< 0.001
|
|
Charlson Comorbidity Indexa
|
3 (1–4)
| |
0.085
|
3 (2.3–5.0)
|
1.5 (0–2.8)
|
< 0.001
|
|
Cause of intubation
| | |
< 0.001
| | |
< 0.001
|
|
Cardiac arrest
|
1 (2.4%)
|
3 (15.8%)
| |
0 (0.0%)
|
4 (11.1%)
| |
|
Neurological distress
|
5 (12.2%)
|
13 (68.4%)
| |
1 (4.2%)
|
17 (47.2%)
| |
|
Post-operative status
|
0 (0%)
|
1 (5.3%)
| |
0 (0.0%)
|
1 (2.8%)
| |
|
Respiratory
|
35 (85.4%)
|
2 (10.5%)
| |
23 (95.8%)
|
14 (38.9%)
| |
|
PaO2/FiO2 ratio
|
212 (133.5–299)
|
431 (321–458)
|
< 0.001
|
222 (131.3–301.0)
|
323 (184.3–442.5)
|
0.022
|
|
Severity
| | | | | | |
|
APACHE II scorea
|
20 (16–24)
|
22 (17–25)
|
0.202
|
20.5 (16.3–24.0)
|
21 (17–25)
|
0.634
|
|
SOFA scorea
|
7 (6–9)
|
6 (4–9)
|
0.117
|
7 (6–9)
|
7 (5–9)
|
0.569
|
|
GCSa
|
8 (6–11)
|
6 (5–9)
|
0.074
|
8.5(6.0–10.8)
|
7.5 (6–9)
|
0.303
|
|
Extubation success in 3 weeks
|
23 (56.1%)
|
11 (57.9%)
|
0.999
|
14 (58.3%)
|
20 (55.6%)
|
0.999
|
|
28-day all-cause mortality
|
12 (29.3%)
|
6 (31.6%)
|
0.999
|
7 (29.2%)
|
11 (30.6%)
|
0.999
|
|
Final hospital mortality
|
19 (46.3%)
|
6 (31.7%)
|
0.4
|
11 (45.8%)
|
14 (38.9%)
|
0.606
|
|
MV durationa
|
13 (8–18)
|
10 (7–16)
|
0.335
|
13 (8–17.5)
|
10 (7.0–16.8)
|
0.384
|
|
CRP (mg/dl)
|
133 (45–213.5)
|
21 (5–132)
|
0.008
|
124.5 (62.8–192.0)
|
94 (8.0–194.0)
|
0.127
|
- NHAI nursing-home- and hospital-associated infections, ARDS acute respiratory distress syndrome, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment, GCS Glasgow Coma Scale, MV mechanical ventilation, CRP C-reactive protein
- a Median (interquartile range)
- b Frequency (%)
